Compare Eversource Energy (D/B/A) Common Stock (ES) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eversource Energy (D/B/A) Common Stock vs Summit Therapeutics Inc — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $67 (market cap $25.11B), while Summit Therapeutics Inc trades at $15 (market cap $12.07B). The key difference: Eversource Energy (D/B/A) Common Stock is far larger — about 2.1× Summit Therapeutics Inc's market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.72% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and Summit Therapeutics Inc for 16 Days on average.
| ES | SMMT | |
|---|---|---|
Market Cap | $25.11B | $12.07B |
Volume | 3,164,400 | 4,658,232 |
Sector | Utilities | Health |
52-Week High | $76.21 | $26.38 |
52-Week Low | $63.28 | $12.43 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $55.18B | $11.40B |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today despite recent positive catalysts including a $2 billion strategic investment from AstraZeneca announced September 28, 2026. The stock shows bullish technical signals with strong institutional support, though fundamentals reflect a pre-revenue biotech with significant losses (-$1.08B net income in 2025) and negative ROE of -192.5%. Recent clinical trial collaborations with major pharma partners highlight the company's promising ivonescimab cancer drug pipeline.
The outlook balances substantial upside potential from AstraZeneca's validation and clinical progress against high execution risks typical of developmental biotechs. With 65% analyst buy ratings and a $29.33 consensus target suggesting 89% upside, the stock offers high-risk/high-reward exposure to innovative cancer therapeutics, dependent on successful drug development and regulatory approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
